Loading
Cholangiocarcinoma and Gallbladder Cancer Studies / Hepatocellular Carcinoma Treatment and Prognosis / Organ Transplantation Techniques and Outcomes · Journal article
Signal Transduction and Targeted Therapy · August 11, 2026
Encouraging direction, but not yet definitive.
This multicenter retrospective study compares a novel temperature-sensitive liquid embolic agent (T-TACE) with drug-eluting bead TACE (D-TACE) in 328 BCLC B/C HCC patients using propensity weighting. T-TACE demonstrated significantly higher objective response rates (54.11% vs. 27.78% by RECIST 1.1), prolonged median PFS (12.0 vs. 9.0 months), and OS (24.0 vs. 15.0 months) with a favorable safety profile, with benefits sustained across high-risk subgroups.
Multicenter retrospective real-world study with inverse probability of treatment weighting. 328 patients with BCLC stage B/C hepatocellular carcinoma across multiple centers in China.. Intervention: Temperature-sensitive liquid embolic agent transarterial chemoembolization (T-TACE). Compared with: Drug-eluting bead transarterial chemoembolization (D-TACE). n = 328. Multicenter study across China; exact number of centers not specified in abstract..
T-TACE achieved superior ORR by RECIST 1.1: 54.11% vs. 27.78% (P < 0.001) T-TACE achieved superior ORR by mRECIST: 73.56% vs. 54.93% (P = 0.002) Median PFS: 12.0 months (T-TACE) vs. 9.0 months (D-TACE), HR = 0.67, P = 0.001
T-TACE associated with lower incidences of hepatic and gastrointestinal toxicities including any-grade ALT elevation and hyperbilirubinemia
If confirmed in a randomized trial, these results would support adoption of temperature-sensitive liquid embolic TACE over drug-eluting bead TACE as first-line TACE in intermediate-to-advanced HCC. The magnitude of OS benefit (HR 0.49) and consistent effect across high-risk subgroups are noteworthy, but the retrospective design limits definitive clinical recommendation.
A multicenter retrospective real-world study with propensity weighting showing clinically meaningful improvements in response rates, PFS, and OS for a novel embolic agent versus standard care, but limited by retrospective design and real-world (non-randomized) conduct.
As stated by the source record.
Quoted from the source exactly as published.
If confirmed in a randomized trial, these results would support adoption of temperature-sensitive liquid embolic TACE over drug-eluting bead TACE as first-line TACE in intermediate-to-advanced HCC. The magnitude of OS benefit (HR 0.49) and consistent effect across high-risk subgroups are noteworthy, but the retrospective design limits definitive clinical recommendation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Transarterial chemoembolization (TACE) remains a cornerstone therapy for intermediate-to-advanced hepatocellular carcinoma (HCC); however, the optimal embolic platform remains uncertain. This multicenter, retrospective, real-world study (Clinical trial registration number: ChiCTR2500113198) conducted across China compared a novel temperature-sensitive liquid embolic agent, TempSLE-TACE (T-TACE), with conventional drug-eluting bead TACE (D-TACE) in 328 patients with Barcelona Clinic Liver Cancer (BCLC) stage B/C HCC. Following inverse probability of treatment weighting (IPTW), T-TACE achieved significantly superior objective response rates (ORRs) compared with D-TACE according to both RECIST 1.1 criteria (54.11% vs. 27.78%, P < 0.001) and mRECIST criteria (73.56% vs. 54.93%, P = 0.002). T-TACE was additionally associated with significantly prolonged progression-free survival (median PFS: 12.0 vs. 9.0 months; HR = 0.67, P = 0.001) and overall survival (median OS, 24.0 vs. 15.0 months; HR = 0.49, P < 0.001). Moreover, T-TACE demonstrated a favorable safety profile, with lower incidences of hepatic and gastrointestinal toxicities, including any-grade alanine aminotransferase elevation and hyperbilirubinemia. Subgroup analyses further demonstrated consistent OS, PFS, and ORR benefits across major clinical subgroups, with effect sizes remaining significantly favorable in high-risk populations, including advanced portal vein tumor thrombosis type Vp4, baseline AFP > 1000 ng/mL, and PIVKA-II > 2000 mAU/mL. Exploratory histo-molecular and spatial transcriptomic analyses suggested that T-TACE may promote immune microenvironment remodeling through enhanced Th17-cell infiltration and CD8⁺ T-cell activation, whereas incomplete embolization after D-TACE was more frequently associated with residual intermediate-state tumor cells and an immunosuppressive microenvironment. Collectively, these findings provide preliminary evidence supporting T-TACE as a promising real-world therapeutic strategy for intermediate-to-advanced HCC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.